

08/05/2015 **BioSig prepares uplisting to NASDAQ in early 2016, chairman says**

Proprietary Intelligence

## Story

**BioSig Technologies** (OTCQB: BSGM) is moving forward with plans to uplist to NASDAQ, expecting to complete it by early 2016. Co-founder and Executive Chairman Kenneth Londoner told this news service.

The Minneapolis, Minnesota-based medical device company, which currently has a market value of about USD 24.8m, has retained **Laidlaw & Co** as its financial advisor, while **Wilson Sonsini Goodrich & Rosati** and **Haynes and Boone** are legal advisors, Londoner said. Listing advisor **Donohoe Advisory Associates** is also advising BioSig, Londoner said.

David Weild, former NASDAQ vice chairman, joined BioSig's board in May and now chairs the audit committee, as the company heads towards an uplisting, Londoner said.

The uplisting will provide investors a better opportunity to participate in the high-growing electrophysiology (EP) market, said Londoner. Globally, the market is estimated to be USD 3bn, with a 12.1% compounded annual growth rate. The EP market is expected to grow to USD 5.5bn by 2019, with the US accounting for 60% of the market.

BioSig is in a solid financial position, especially after securing a USD 4m private placement in March, Londoner said. As this news service previously reported, it is BioSig's business model to grow through private funding, then move to a thinly-traded exchange and finally a national one. It allows the company to sustain value for shareholders as it advances its products.

Aside from the uplisting, Londoner noted the strong M&A trend in the EP sector, including the USD 250m deal between **Abbott Laboratories**(NYSE: ABT) and another EP device provider **Topera Medical** in 2014 .

Since BioSig's Pure EP system is an 'add-on' technology designed to support EP procedures, Londoner said the company could attract interest from big players such as **General Electric** (NYSE:GE), **St. Jude Medical** (NYSE:STJ), **Boston Scientific**(NYSE:BSX) and **Johnson & Johnson** (NYSE:JNJ). As reported, the takeover probability was factored into the company's plans when BioSig was formed.

Currently, the company is conducting two pre-clinical trials of PURE EP system at UCLA Cardiac Arrhythmia Center and Mayo Clinic in Minnesota. Mayo Clinical data will likely be released by the end of 2015. Following the studies, the company anticipates to seek 510 (k) clearance from Food and Drug Administration in the first half of 2016, followed by the commercial launch by the end of the year, Londoner said.

by Yiqin Shen

**Source** Proprietary Intelligence

**Value**

**Stake** N/A

**Value**

<b>Target</b>	BioSig Technologies	
<b>Consultant</b>	Donohoe Advisory Associates LLC	
<b>Lawyer</b>	Haynes and Boone LLP	
<b>Financial advisor</b>	Laidlaw & Company (UK) Ltd.	
<b>Lawyer</b>	Wilson Sonsini Goodrich & Rosati P.C.	
<b>Bidder</b>	Johnson & Johnson	
<b>Bidder</b>	General Electric Company	
<b>Bidder</b>	Boston Scientific Corporation	
<b>Bidder</b>	St. Jude Medical Inc	
<b>Sectors</b>	Medical	
<b>SubSectors</b>	Medical equipment & services	
<b>Topics</b>	Advisory Appointment Other M&A Intelligence	
<b>Intel Type</b>	Companies for sale M&A Medical Devices	
<b>Countries</b>	USA	
<b>Intel. Grade</b>	Confirmed	
<b>Intelligence ID</b>	2070160	